Keywords: expanded, indication, eisai, ontakr, japanese, drugmaker, denileukin
Expanded US indication for Eisai's Ontakr
Article | 20 October 2008
Japanese drugmaker Eisai's Ontakr (denileukin diftitox) has been approved in the USA for patients with persistent or recurrent cutaneous T-cell ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
